



Synthesis of Tetrahydroquinoline Derivatives from α -CF₃-N-Arylaldimine and Vinyl Ethers

Benoît Crousse, Jean-Pierre Bégué*, Danièle Bonnet-Delpon

Laboratoire BIOCIS associé au CNRS, Centre d'Etudes Pharmaceutiques, Rue J.B. Clément, 92296 Châtenay-Malabry, France

Received 2 April 1998; accepted 8 June 1998

Abstract :

BF₃.Et₂O or Yb(OTf)₃ catalyzed [4+2] cycloaddition reaction of α -CF₃-N-arylaldimines with nucleophilic olefins afforded CF₃-substituted tetrahydroquinoline derivatives. © 1998 Elsevier Science Ltd. All rights reserved.

Keywords : aza-Diels-Alder; α -CF₃-N-Arylaldimine; Lewis acids, vinyl ethers.

Tetrahydroquinoline derivatives are an important class of natural products and exhibit biological activities in various fields [1]. Lewis acid promoted aza-Diels-Alder reactions between N-arylimines and different dienophiles is one of the most powerful synthetic tools for constructing N-containing six-membered heterocyclic compounds such as tetrahydroquinolines [2-12]. Since the pioneering work of Povarov [13], this reaction has been extensively studied with the use of different Lewis acids such as lanthanide salts [14-16] and search for new reaction conditions [14,15,17]. Considering the extraordinary potential of fluoroalkyl containing biologically relevant molecules due to the unique feature of fluorine atom [18], we envisaged to study the aza-Diels-Alder reaction with α -CF₃-N-arylaldimines. Although this cycloaddition is known to be less efficient with alkyl aldimines, a CF₃ substituent lowers the LUMO level [19] and could favor cycloaddition reactions [20]. However concomitantly a trifluoromethyl group also significantly reduces the basicity of carbonyl and imine groups and hence the strength of complexation with a Lewis acid [19]. Effectively the only example of aza-Diels-Alder reaction reported in fluorinated series, is a cationic dipolar reaction starting from a preformed aryliminium salt [21].

In this paper we describe the synthesis of tetrahydroquinoline derivatives bearing a CF₃ group at C-2 position, by an intermolecular [4+2] cycloaddition of the α -CF₃-N-arylaldimine **1** derived from trifluoroacetaldehyde and *p*-anisidine [22], with electron-rich alkenes under Lewis acid catalysis.

The reaction has been explored with two different catalysts, BF₃.Et₂O and Yb(OTf)₃. With BF₃.Et₂O, the reaction between aldimine **1** and enol ether **2a** was first performed at room temperature and led to a complex mixture. However when the reaction was carried out at -78°C in toluene (it was the best solvent among all other tested such as dichloromethane, ether, THF) in presence of 10% of Lewis acid, the tetrahydroquinoline **3a** was obtained in a 56% yield. Reactions with other enol ethers **2b-d** afforded tetrahydroquinoline derivatives in moderate to good yields and with a high level of selectivity (Table 1). Tetrahydroquinolines **3a** and **3b**

* Fax : 33 1 46 83 57 40; e-mail : Jean-Pierre.Begue@cep.u-psud.fr

were obtained as only one regio- and stereoisomer. No other isomer could be detected. Relative configuration of the newly created stereocenters is *cis*, indicating on endo approach of the enol ether. The reaction with the 2,3-dihydrofuran **2c** afforded the tetrahydroquinoline **3c** as a 90/10 mixture of *cis* and *trans* diastereoisomer which were separated by column chromatography. With the 3,4-dihydro-2H-pyran **2d**, one equivalent of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ was required to obtain the tetrahydroquinoline **3d** in a 64/36 ratio. All structures were determined by ^1H , ^{19}F and ^{13}C NMR spectra. Stereochemistry was assigned by coupling constants and by $\{^{19}\text{F}\}$ - ^1H Nuclear Overhauser Effect measurements.








Table 1 : Syntheses of tetrahydroquinoline derivatives ($\text{BF}_3 \cdot \text{Et}_2\text{O}$)

Entry	2	t	3	<i>cis/trans</i>	Rdt (%) ^a
1	 2a	20 min		100/0	56
2	 2b	30 min		100/0	60
3	 2c	70 min		90/10	84
4	 2d	2 h		64/36	86 ^b

a) Isolated yield

b) 1 eq of Lewis Acid was required


For comparison we also explored this reaction under $\text{Yb}(\text{OTf})_3$ catalysis. Results were similar to those obtained with $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Table 2). However some slight differences were observed. With **2c** and **2d**, tetrahydroquinolines **3c**, **3d** were obtained as a 70/30 mixture of *cis* and *trans* isomers. In the case of vinyl ether **2d**, only 5% of lanthanide was required. Moreover the great advantage is that this reaction occurred cleanly at room temperature.

Table 2 : Syntheses of tetrahydroquinoline derivatives ($\text{Yb}(\text{OTf})_3$, MeCN, r.t.)

Entry	2	t	3	<i>cis/trans</i>	Rdt (%) ^a
1	2a	15 min	3a	100/0	56
2	2b	40 min	3b	100/0	67
3	2c	30 min	3c	70/30	74
4	2d	6 h	3d	70/30	87

a) Isolated yield

The tetrahydroquinolines **3a** and **3b** could be easily converted into quinoline **4** under acidic condition (HCl 2N) [14] in MeCN over 16 hours at room temperature.



In conclusion, the electronwithdrawing character of a CF_3 group has been proved to be very effective in [4+2] aza-Diels-Alder reactions. The $\alpha\text{-CF}_3\text{-N-arylimine 1}$ could react with various vinyl ethers to afford tetrahydroquinoline derivatives bearing a CF_3 substituent at C-2 position, in moderate to good yields.

Typical Procedure for the Reaction between the imine 1 and dihydrofuran 2c :

With $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (Table 1)

To a solution of **1** (1.5 mmol, 306 mg) in dry toluene (5 mL) was added, at -78°C , $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (0.15 mmol, 0.02 mL). After stirring for 10 minutes, 2,3-dihydrofuran **2c** (2.26 mmol, 0.17 mL) in dry toluene (1 mL) was added. The reaction mixture was stirred for 70 minutes, then saturated aqueous NaHCO_3 (10 mL) was added and the product was extracted with ether (10 mL x 3). After usual workup, a chromatography on silica gel (petroleum ether/ethylacetate : 80/20) afforded 345 mg (84%) of **3c** (*cis/trans* : 90/10).

Isomer *cis*:

^1H NMR (CDCl_3 , 400 MHz) : δ 6.89 (d, 1H, $J=3$ Hz); 6.72 (dd, 1H, $J=9, 2.9$ Hz); 6.58 (d, 1H, $J=9$ Hz); 5.2 (d, 1H, $J=7.5$ Hz); 4.01 (qddd, 1H, $J=7, 2.4, 1.5, 0.7$ Hz); 3.87 (td, 1H, $J=8, 7.4$ Hz); 3.81 (td, 1H, $J=9, 4$ Hz); 3.75 (s, 3H, OMe); 3.67 (s, 1H, NH); 2.84 (m, 1H); 2.22 (m, 1H); 1.99 (m, 1H). ^{13}C NMR (CDCl_3 , 50 MHz) : δ 153.9, 135.8, 125.3, 123.1, 116.7, 116.1, 113.1, 75.3, 66.8, 54.7, 37.2, 24.1. ^{19}F NMR (CDCl_3 , CFCl_3) : δ -76.1 (d, $J=7$ Hz).

isomer *trans*

^1H NMR (CDCl_3 , 400 MHz) : δ 6.9 (d, 1H, $J=3$ Hz); 6.74 (dd, 1H, $J=9$, 3 Hz); 6.58 (d, 1H, $J=9$ Hz); 4.77 (d, 1H, $J=6.5$ Hz); 3.93 (td, 1H, $J=8.5$, 5 Hz); 3.85 (td, 1H, $J=8$, 7.2 Hz); 3.75 (s, 3H, OMe); 3.56 (qdd, 1H, $J=7$, 6.6, 2 Hz); 2.27 (dtd, 1H, $J=13$, 8, 5 Hz); 2.12 (dq, 1H, $J=13$, 7 Hz). ^{13}C NMR (CDCl_3 , 50 MHz) : δ 153.0, 135.0, 125.5, 121.0, 115.8, 116.4, 113.5, 73.9, 65.6, 55.7, 54.8, 35.9, 29.2. ^{19}F NMR (CDCl_3 , CFCl_3) : -75.95 (d, $J=7\text{Hz}$).

With $\text{Yb}(\text{OTf})_3$ (Table 2)

To a solution of $\text{Yb}(\text{OTf})_3$ (0.05 mmol, 21 mg) in MeCN (1 mL) was added imine **1** (1 mmol, 203 mg) and **2c** (1.5 mmol, 0.13 mg) in MeCN (1.5 mL) at r.t.. The reaction mixture was stirred for 30 minutes, then a saturated aqueous NaHCO_3 solution (10 mL) was added and the product was extracted with ether (10 mL x 3). After usual workup, a chromatography on silica gel afforded 202 mg (74%) of **3c** (*cis/trans* : 70/30).

Acknowledgements: One of the authors, B. Crousse thanks Fondation pour la Recherche Médicale for a financial support, and Dr Maruto (Central Glass) for starting materials.

References :

- [1] a) Johnson, J.V.; Rauckman, S.; Baccanari, P.D.; Roth, B. J. Med. Chem., 1989;32:1942-1949.
b) Carling, R.W.; Leeson, P.D.; Moseley, A.M.; Baker, R.; Foster, A.C.; Grimwood, S.; Kemp, J.A.; Marshall G.R. J. Med. Chem., 1992;35:1942-1953.
c) Leeson, P.D.; Carling, R.W.; Moore, K.W.; Moseley, A.M.; Smith, J.D.; Stevenson G.; Chan, T.; Baker, R.; Foster, A.C.; Grimwood, S.; Kemp, J.A.; Marshall G.R.; Hoogsteen, K., J. Med. Chem., 1992;35:1954-1968.
d) Carling, R.W.; Leeson, P.D.; Moseley, A.M.; Smith, J.D.; Saywell, K.; Tricklebank, M.D.; Kemp, J.A.; Marshall, G.R.; Foster, A.C.; Grimwood, S. Bioorganic & Medicinal Chemistry Letters, 1993;3:65-70.
- [2] Weinreb, S.M. Comprehensive Organic Synthesis, Trost, B.M., Fleming, I., Eds., Pergamon: Oxford, 1991, Vol.5,401
- [3] Boger, D.L.; Weinreb, S.M. Hetero Diels-Alder Methodology in Organic Synthesis, academic: San Diego, 1987, Chaps.2 and 9.
- [4] Nomura, Y.; Kimura, M.; Takeuchi, Y.; Tomoda, S. Chemistry Letters, 1978:267-270.
- [5] Boger, D.L. Tetrahedron, 1983; 39:2869-2939.
- [6] Kametani, T.; Takeda, H.; Suzuki, Y.; Honda, T. Heterocycles, 1984;22:275-276.
- [7] Kametani, T.; Takeda, H.; Suzuki, Y.; Kasai, H.; Honda, T. Heterocycles, 1986; 24: 3385-3395.
- [8] Koichi, N.; Takanori, S. Heterocycles, 1993; 35: 1039-1053.
- [9] Lucchini, V.; Prato, M.; Scorrano, G.; Tecilla, P. J. Org. Chem., 1988; 53:2251-2258.
- [10] Lucchini, V.; Prato, M.; Scorrano, G.; Stivanello, M.; Valle, G. J. Chem. Soc. Perkin Trans. 2, 1992: 259-266.
- [11] Borriero, E.; Lucchini, V.; Prato, M.; Scorrano, G.; Stivanello, M. J. Heterocyclic Chem., 1988;25:1831-1833.
- [12] Borriero, E.; Prato, M.; Scorrano, G.; Stivanello, M.; Lucchini, V.; Valle, G. J. Chem. Soc. Perkin Trans. 1, 1989:2245-2250.
- [13] Povarov, L.S. Russ. Chem. Rev., Engl. Transl, 1967; 36:656-675.
- [14] Makioka, Y.; Shindo, T.; Taniguchi, Y.; Takaki, K.; Fujiwara, Y. Synthesis, 1995;801-804.
- [15] Kobayashi, S.; Ishitani, H.; Nagayama, S. Chemistry Letters, 1995;423-424.
- [16] Kobayashi, S.; Ishitani, H.; Nagayama, S. Synthesis, 1995;1195-1202.
- [17] Annunziata, R.; Cinquini, M.; Cozzi, F.; Molteni, V.; Schupp, O., Tetrahedron, 1997;28:9715-9726.
- [18] a) Organofluorine Compounds in Medicinal Chemistry and Biochemical Applications, Filler, R.; Kobayashi, Y.; Yagupolski, L., 1993; Eds Elsevier, Amsterdam.
b) Biomedical Frontiers of Fluorine Chemistry, Ojima, I.; McCarthy, J.R.; Welch, J.T. Eds.A.C.S.:Washington, D.C., 1996;228.
c) Edwards, P.N. Use of Fluorine in Chemotherapy. In Organofluorine Chemistry: Principles and commercial Applications, Banks, R.E.; Tatlow, J.C., Plenum Press, 1994, N.Y., 501-541.
- [19] a) Linderman, R.J.; Jamois, E.A. J. Fluorine Chem.,1991;53:79-91.
b) Mikami, K.; Yajima, T.; Terada, M.; Uchimaru, T. Tetrahedron Lett.,1993;34:7591-7194.
c) Drumond, D.F.; McMahon, T.B. J. Phys. Chem.,1981;85:3746-3748.
- [20] Bonnet-Delpon, D.; Bégué, J.P.; Lequeux, T.; Ourévitche, M., Tetrahedron, 1996;52:59-70.
- [21] Guanti, G.; Banfi, L.;Narisano, E.; Scolastico, C.; Bosone, E. Synthesis, 1985; 609-611.
- [22] a) Fuchigami, T.; Ichikawa, S.; Kandeel, Z.E.; Konno, A.; Nonaka, T. Heterocycles, 1990;31:415-417.
b) Fuchigami, T.; Ichikawa, S. J. Org. Chem., 1994;59:607-615.